title: Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
abstract: The effect of administration of subtype selective dopamine (DA) agonists on the 6-hydroxydopamine (6-OHDA) lesion-induced increase of striatal preproenkephalin (PPE) mRNA was examined by dot-blot hybridization. Eight days following a unilateral 6-OHDA lesion of the substantia nigra pars compacta (SNc), PPE mRNA levels in the ipsilateral striatum were increased approximately two-fold. Administration of the D2 DA agonist, quinpirole, dose-dependently attenuated the 6-OHDA lesion-induced increase in striatal PPE mRNA. The effect of quinpirole was blocked by coadministration of the D2 DA antagonist eticlopride. In contrast, administration of the D1 DA agonist, SKF 38393, either dose-dependently augmented or had no effect on the 6-OHDA lesion-induced increase in striatal PPE mRNA. In the contralateral striatum, administration of quinpirole decreased PPE mRNA, while administration of SKF 38393 increased PPE mRNA compared to sham lesioned control levels. These data suggest the action of DA at D1 and D2 DA receptors differentially regulates striatal PPE mRNA levels and the apparent inhibition of ENK biosynthesis by DA is mediated via an interaction with D2 DA receptors.
authors.affiliation: Department of Neuroscience, University of Virginia Health Sciences Center, Charlottesville 22908.
authors.forename: A E
authors.initials: AE
authors.lastname: Pollack
authors.forename: G F
authors.initials: GF
authors.lastname: Wooten
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology*; D000818:Animals; D015152:Blotting, Northern; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology*; D003891:Desipramine / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D004745:Enkephalins / Q000235:genetics* / Q000378:metabolism; D004873:Ergolines / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects; D007700:Kinetics; D008297:Male; D009693:Nucleic Acid Hybridization; D015345:Oligonucleotide Probes; D016627:Oxidopamine / Q000008:administration & dosage / Q000494:pharmacology*; D011498:Protein Precursors / Q000235:genetics* / Q000378:metabolism; D019257:Quinpirole; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012016:Reference Values; D012457:Salicylamides / Q000494:pharmacology*; D013238:Stereotaxic Techniques
chemical_list: D004745:Enkephalins; D004873:Ergolines; D015345:Oligonucleotide Probes; D011498:Protein Precursors; D012333:RNA, Messenger; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D016627:Oxidopamine; C033660:preproenkephalin; C045989:eticlopride; D003891:Desipramine; D004298:Dopamine